Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 751703, 8 pages
http://dx.doi.org/10.1155/2015/751703
Clinical Study

Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate

Division of Hematology-Oncology, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Received 29 April 2015; Accepted 8 June 2015

Academic Editor: Xu Dong Zhang

Copyright © 2015 Shi-Long Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Mantadakis, P. D. Cole, and B. A. Kamen, “High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?” Pharmacotherapy, vol. 25, no. 5, pp. 748–755, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. W. E. Evans, W. R. Crom, C. F. Stewart et al., “Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia,” The Lancet, vol. 1, no. 8373, pp. 359–362, 1984. View at Publisher · View at Google Scholar · View at Scopus
  3. W. E. Evans, W. R. Crom, M. Abromowitch et al., “Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect,” The New England Journal of Medicine, vol. 314, no. 8, pp. 471–477, 1986. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Choeyprasert, S. Pakakasama, N. Sirachainan et al., “Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 22, pp. 9823–9829, 2014. View at Publisher · View at Google Scholar
  5. Y. Liu, Y. Xu, N. Lin, S. Jiang, Y. Wang, and Z. Ye, “High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma,” Cell Biochemistry and Biophysics, vol. 71, no. 2, pp. 1097–1104, 2015. View at Publisher · View at Google Scholar
  6. Y. Gómez-Gómez, J. Organista-Nava, C. Rangel-Rodriguez et al., “Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia,” Oncology Letters, vol. 8, pp. 731–735, 2014. View at Publisher · View at Google Scholar
  7. Y. Gómez-Gómez, J. Organista-Nava, M. V. Saavedra-Herrera et al., “Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms,” Experimental and Therapeutic Medicine, vol. 3, no. 4, pp. 665–672, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. I. J. Cohen, “Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system,” Journal of Pediatric Hematology/Oncology, vol. 26, no. 3, pp. 156–163, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Štěrba, D. Valík, V. Bajčiová, V. Kadlecová, V. Gregorová, and D. Mendelová, “High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?” Neoplasma, vol. 52, no. 6, pp. 456–463, 2005. View at Google Scholar · View at Scopus
  10. K. Schmiegelow, “Advances in individual prediction of methotrexate toxicity: a review,” British Journal of Haematology, vol. 146, no. 5, pp. 489–503, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. V. Relling, D. Fairclough, D. Ayers et al., “Patient characteristics associated with high-risk methotrexate concentrations and toxicity,” Journal of Clinical Oncology, vol. 12, no. 8, pp. 1667–1672, 1994. View at Google Scholar · View at Scopus
  12. W. Xu, Y. Tang, H. Song, S. Shi, and S. Yang, “Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 10, pp. 688–693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Piard, F. Bressolle, M. Fakhoury et al., “A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 4, pp. 609–620, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Min, F. Qiang, L. Peng, and Z. Zhu, “High dose methotrexate population pharmacokinetics and bayesian estimation in patients with lymphoid malignancy,” Biopharmaceutics and Drug Disposition, vol. 30, no. 8, pp. 437–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Aumente, D. S. Buelga, J. C. Lukas, P. Gomez, A. Torres, and M. J. García, “Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia,” Clinical Pharmacokinetics, vol. 45, no. 12, pp. 1227–1238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Skärby, P. Jönsson, L. Hjorth et al., “High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL),” Cancer Chemotherapy and Pharmacology, vol. 51, no. 4, pp. 311–320, 2003. View at Google Scholar · View at Scopus
  17. K. Fukuhara, K. Ikawa, N. Morikawa, and K. Kumagai, “Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data,” Journal of Clinical Pharmacy and Therapeutics, vol. 33, no. 6, pp. 677–684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Tang, X. Xu, H. Song, S. Yang, S. Shi, and J. Wei, “Long-term outcome of childhood acute lymphoblastic leukemia treated in China,” Pediatric Blood and Cancer, vol. 51, no. 3, pp. 380–386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. P. C. Adamson, F. M. Balis, W. Berg, and S. M. Blaney, “General principles of chemotherapy,” in Principles and Practice of Pediatric Oncology, P. A. Pizzo and D. G. Poplack, Eds., pp. 290–365, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 5th edition, 2005. View at Google Scholar
  20. H. T. Abelson, M. T. Fosburg, G. P. Beardsley et al., “Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine,” Journal of Clinical Oncology, vol. 1, no. 3, pp. 208–216, 1983. View at Google Scholar · View at Scopus
  21. L. Hempel, J. Misselwitz, C. Fleck et al., “Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function,” Medical and Pediatric Oncology, vol. 40, no. 6, pp. 348–354, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Ylinen, K. Jahnukainen, U. M. Saarinen-Pihkala, and T. Jahnukainen, “Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia,” Pediatric Blood & Cancer, vol. 61, no. 12, pp. 2199–2202, 2014. View at Publisher · View at Google Scholar
  23. P. Joannon, I. Oviedo, M. Campbell, and J. Tordecilla, “High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance,” Pediatric Blood and Cancer, vol. 43, no. 1, pp. 17–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. Borsi and P. J. Moe, “Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukmia in children,” Cancer, vol. 60, no. 12, pp. 3020–3024, 1987. View at Publisher · View at Google Scholar · View at Scopus